ArticleMedicine2026
Inflammation-metabolism composite (CRP-triglyceride-glucose index) predicts all-cause and cardiovascular mortality in MASLD with advanced fibrosis: Evidence from a national NHANES cohort.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent and associated with metabolic dysfunction, systemic inflammation, and increased cardiovascular risk. The C-reactive protein-Triglyceride-Glucose Index (CTI) is a novel composite biomarker reflecting low-grade inflammation and insulin resistance. However, its prognostic value for long-term mortality in patients with MASLD and advanced fibrosis remains unclear. Therefore, this study aimed to investigate the association between CTI and the risk of all-cause and cardiovascular mortality in individuals with MASLD using a nationally representative cohort. We used data from National Health and Nutrition Examination Survey 2001 to 2018 and included 8791 adults with MASLD. Advanced fibrosis was defined by FIB-4, NAFLD Fibrosis Score, and AST-to-Platelet Ratio Index. Survey-weighted Cox models evaluated associations between CTI (per standard deviation increase) and all-cause and cardiovascular mortality. Restricted cubic splines examined dose-response patterns. Effect modification by sex, age, and race/ethnicity was assessed in stratified analyses. Over follow-up, 1806 deaths occurred. Higher CTI was independently associated with increased all-cause (HR 1.16, 95% confidence interval [CI]: 1.12-1.20) and cardiovascular mortality (HR 1.12, 95% CI: 1.04-1.20) in MASLD. Among participants with advanced fibrosis, CTI remained associated with all-cause (HR 1.14, 95% CI: 1.07-1.23) and cardiovascular mortality (HR 1.14, 95% CI: 1.01-1.29). Splines showed a U-shaped association between CTI and mortality in MASLD (nadir CTI ~7.5-7.9) but an approximately linear positive association in advanced fibrosis. Associations were stronger in women, older adults, and racial/ethnic minorities. Our observational findings suggest that CTI is associated with long-term all-cause and cardiovascular mortality in MASLD and advanced fibrosis. As a simple, integrative biomarker, CTI may help refine early risk stratification in high-risk MASLD populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.